JPMorgan Chase & Co. Lowers Endologix (ELGX) to Underweight
JPMorgan Chase & Co. cut shares of Endologix (NASDAQ:ELGX) from a neutral rating to an underweight rating in a report released on Tuesday morning, Marketbeat Ratings reports.
A number of other equities research analysts have also commented on the company. ValuEngine lowered Endologix from a sell rating to a strong sell rating in a research report on Sunday, December 31st. BidaskClub lowered Endologix from a buy rating to a hold rating in a research report on Friday, December 15th. Piper Jaffray Companies restated an overweight rating on shares of Endologix in a research report on Tuesday, December 12th. Canaccord Genuity reiterated a hold rating and set a $5.00 price target on shares of Endologix in a report on Wednesday, November 8th. Finally, Stifel Nicolaus reduced their price target on Endologix from $6.00 to $5.50 and set a hold rating for the company in a report on Wednesday, November 8th. Two investment analysts have rated the stock with a sell rating, nine have issued a hold rating and one has given a buy rating to the stock. The company presently has a consensus rating of Hold and an average price target of $5.41.
Shares of Endologix (ELGX) traded down $0.09 during midday trading on Tuesday, reaching $5.12. The company’s stock had a trading volume of 247,300 shares, compared to its average volume of 1,010,500. Endologix has a 12-month low of $4.08 and a 12-month high of $7.66. The firm has a market cap of $434.79, a price-to-earnings ratio of -5.51 and a beta of 0.72. The company has a debt-to-equity ratio of 2.61, a current ratio of 2.90 and a quick ratio of 2.11.
COPYRIGHT VIOLATION NOTICE: “JPMorgan Chase & Co. Lowers Endologix (ELGX) to Underweight” was first published by Marea Informative and is owned by of Marea Informative. If you are reading this piece of content on another publication, it was illegally copied and reposted in violation of U.S. and international copyright & trademark laws. The legal version of this piece of content can be accessed at https://www.mareainformativa.com/2018/01/05/jpmorgan-chase-co-lowers-endologix-elgx-to-underweight.html.
Endologix Company Profile
Endologix, Inc is engaged in developing, manufacturing, marketing and selling medical devices for the treatment of aortic disorders. The Company’s products are intended for the treatment of abdominal aortic aneurysms (AAA). The AAA products are built on one of two platforms, including traditional minimally invasive endovascular repair (EVAR) or endovascular sealing (EVAS), its solution for sealing the aneurysm sac while maintaining blood flow through two blood flow lumens.
Receive News & Ratings for Endologix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endologix and related companies with MarketBeat.com's FREE daily email newsletter.